US FDA cleared IND application allowing for the start of Ph 1 trial of SP-3164 in patients with R/R NHL
“US Food and Drug Administration has cleared its investigational new drug (IND) application allowing for the start of a Phase I trial of SP-3164 in patients with relapsed or refractory non-Hodgkin lymphoma. In the trial, expected to begin in the second half of this year, Salarius will also evaluate a gene signature for selecting patients who may respond well to the second-generation targeted protein degrader SP-3164. The dose-escalation portion of the study will involve patients with non-Hodgkin lymphoma, and in a second portion of the study, researchers will assess the activity of the drug in patients with diffuse large B-cell lymphoma, Salarius CEO David Arthur said in a statement.”
Share:
More News
“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing
“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at
“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers
“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.
